KR20230023604A - Anti-obesity composition and oral composition - Google Patents

Abstract

An object of the present invention is an anti-obesity composition capable of promoting gene expression of brown adipocytes or proteins related to their energy-consuming action, such as PGC1α and UCP1, and having an effect of promoting energy-consuming action in brown adipocytes. And to provide a composition for oral use. The composition of the present invention contains tectorigenins and pinitol. It is preferable that the said tectorigenin is tectorigenin. The composition of the present invention can be suitably used as an anti-obesity composition and an oral composition.

Description

Anti-obesity composition and oral composition

The present invention relates to each composition used for anti-obesity, reduction of body fat, promotion of fat metabolism, promotion of fat burning, promotion of heat production, promotion of energy consumption, and oral use. Further, the present invention relates to the use of tectorigenins and pinitol in the production of functional foods for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption. In addition, the present invention relates to a method for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption, using a composition containing tectorigenins and pinitol.

Obesity is deeply related to fat consumption in the body, and fat consumption is specifically achieved by the following mechanism.

When fat mobilizing hormones such as noradrenaline are secreted, hormone-sensitive lipase, which is a lipolysis enzyme, is activated in white fat cells distributed in the skin or intestines, and triglycerides (neutral fats) stored in white fat cells are decomposed, and glycerol and It is converted into free fatty acids and released into the blood. Free fatty acids released into the blood are taken into mitochondria of brown adipocytes distributed in the liver, muscles, and around the clavicle, around the chest, shoulders, etc., and are consumed as heat. In this way, white adipocytes are responsible for storing excess energy in the body as fat, whereas brown adipocytes are responsible for generating heat by burning fat.

As one of the candidate molecules involved in the autonomous regulation of energy consumption, UCP1 and PGC1α are known.

UCP has a function of dissipating energy as heat by deconjugating the oxidative phosphorylation reaction in the mitochondrial inner membrane. Regarding UCP1, the most representative brown cell fat, 1. UCP1 function is decreased in obese animals, 2. UCP1 is increased in animals that are not obese even though they are overfed, and 3. UCP1 gene expression is artificially reduced in mice. is known to be obese and high-expressing mice are thin. In addition, PGC1α is known to mediate the activation of UCP1 by stimulation of the β-adrenergic receptor in brown adipocytes and to promote mitochondrial growth (Non-Patent Document 1).

Therefore, since an anti-obesity effect can be expected by activating UCP1 or PGC1α, drugs or foods with excellent activation of UCP1 or PGC1α are being explored.

On the other hand, various anti-obesity agents are known, including Patent Literature 1, as conventionally aimed at reducing white adipose tissue such as subcutaneous fat.

Japanese Unexamined Patent Publication No. 2017-171654 Japanese Unexamined Patent Publication No. 2009-196931

Journal of the 124th Japanese Medical Association Symposium 「Science of Obesity」 Japanese Medical Association, 2003, p62-70

The action of producing heat by consuming energy such as fatty acids in brown adipocytes (hereinafter also referred to as "energy consuming action") is important in lipid metabolism, and if this action can be activated, the body will be more It can be expected that a large amount of fat is converted into heat and a more effective anti-obesity action is obtained.

However, in each of the above conventional techniques, promotion of the energy consumption action in brown adipocytes has not been studied.

In addition, upon examination by the present inventors, it was found that conventional anti-obesity agents known to be capable of reducing white adipose tissue alone are not sufficient in terms of promoting energy consumption in brown adipocytes. did

The present inventors intensively studied the composition of a composition capable of promoting the energy-consuming action in brown adipocytes by examining the gene expression of proteins such as PGC1α and UCP1 related to the energy-consuming action in brown adipocytes. . As a result, it was found that, surprisingly, the expression of these genes can be promoted by combining specific components, and the excellent effect of promoting the above-mentioned energy consumption is obtained.

The present invention is based on the above knowledge and provides an anti-obesity composition containing tectorigenins and pinitol.

The present invention provides a composition for reducing body fat or promoting fat metabolism containing tectorigenins and pinitol.

The present invention provides a composition for promoting fat burning, promoting heat production, or promoting energy consumption, containing tectorigenins and pinitol.

Further, the present invention provides an oral composition containing tectorigenins and pinitol.

In addition, the present invention provides use of tectorigenins and pinitol for the production of functional foods for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption.

In addition, the present invention provides a method for improving obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production or promoting energy consumption, using a composition containing tectorigenins and pinitol.

According to the present invention, it is possible to provide a useful oral composition containing a composition containing tectorigenins and pinitol, and in particular, gene expression of proteins such as PGC1α and UCP1 related to energy consumption in brown adipocytes. can promote energy consumption in brown adipocytes, and has an effect of promoting energy consumption in brown adipocytes, effective anti-obesity composition, body fat reduction composition, fat metabolism promotion composition, fat burning promotion composition, heat production promotion composition and a composition for promoting energy consumption. In addition, through the effect of promoting the expression of the PGC1α and UCP1 genes, it has the effect of promoting energy consumption in brown adipocytes, thereby preventing obesity, reducing body fat, promoting fat metabolism, promoting fat burning, promoting heat production and energy consumption An oral composition in which each effect of stimulation is effective can be provided. In addition, according to the present invention, the expression of the PGC1α and UCP1 genes can be promoted, and the energy consumption action in brown adipocytes can be promoted, and an effective composition containing tectorigenins and pinitol for obesity improvement can be obtained. use, and a method for improving obesity, using tectorgenins and pinitol as active ingredients.

1 is a graph showing the expression level of PGC1α gene in Examples and Comparative Examples.
Fig. 2 is a graph showing the expression level of the UCP1 gene in Examples and Comparative Examples.

Hereinafter, the present invention will be described in more detail with reference to embodiments of the present invention, but the present invention is not limited thereto. Hereinafter, the anti-obesity composition of the present invention, the composition for reducing body fat, the composition for promoting fat metabolism, the composition for promoting fat burning, the composition for promoting heat production, the composition for promoting energy consumption, and the oral composition are summarized as "the composition of the present invention." 」 is written.

(tectorigenins)

Tectorigenins refer to tectorigenin, glycosides of tectorigenin, and derivatives thereof.

Tectorigenin is one of the flavonoids present in plants such as Iris, and is represented by the molecular formula C ₁₆ H ₁₂ O ₆ , 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy- 4H-1-benzopyran-4-one (5,7-Dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one) or 6-methoxy-5,7-di Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one (6-Methoxy-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4- Sometimes referred to as one). In the present specification, when simply referred to as tectorigenin, it refers to an aglycone type. The chemical formula of tectorigenin is as follows.

The tectorigenin glycoside in the present invention refers to one or two or more sugars selected from monosaccharides and/or sugar acids bound to the above tectorigenin. As the monosaccharide, pentose and hexose are preferable, and one or more types selected from glucose, xylose, mannose, fructose, sorbose, galactose, apiose, and rhamnose are more preferable, and glucose, One or two selected from xylose are particularly preferred. Moreover, as a sugar acid, uronic acid is preferable, and glucuronic acid and galacturonic acid are especially preferable. In glycosides, these sugars and/or sugar acids are usually bonded to hydroxyl groups at the 4' and/or 7 positions of tectorgenin. In the present invention, it is preferably bonded to the 7-position hydroxyl group. The number of sugars and/or sugar acids in the tectrigenin glycoside (also referred to as the number of sugar and/or sugar acid bonds) is, for example, 1 or more and 5 or less, preferably 1 or more and 4 or less; 1 or more and 3 or less are especially preferable. The number of sugars and/or sugar acids refers to the total number of sugars and/or sugar acids. Here, n sugars bound to tectorigenin may mean that linkages of n sugars are bound, or the total number of sugars bound to different sites of tectorigenin may be n. The case where the glycoside contains a sugar acid is also the same.

Examples of the derivative of tectorigenin or its glycoside include compounds in which one or two or more hydrogen atoms in tectorgenin or its glycoside are substituted with substituents. Examples of such a substituent include an amino group, a sulfonic acid group, an alkyl group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 4 carbon atoms. The number of substituents described above in tectorgenins is preferably 8 or less, more preferably 4 or less, and most preferably 0.

The composition of the present invention may use only any one of the above tectorigenin, glycosides thereof, and derivatives thereof, or a mixture of two or more thereof. In particular, in the composition of the present invention, it is preferable that the tectorigenin is tectorigenin and/or a glycoside thereof from the viewpoint of anti-obesity action. Particularly, the composition of the present invention preferably contains tectorigenin as a tectorigenin from the standpoint of being excellent in the effect of accelerating the energy-consuming action in brown adipocytes and being easy to obtain. In the composition of the present invention, tectorigenins may be synthetic organic products or may be extracted from plants or the like.

(Pinitol)

Pinitol is also called 3-O-methyl-D-chiro-inositol and is a type of inositol. Pinitol is contained in plants such as locust beans and clover. In the composition of the present invention, pinitol may be an organic synthetic product or may be extracted from a plant or the like.

In the present invention, the content ratio of tectorgenins and pinitol is preferably within a specific range because gene expression of PGC1α and UCP1 is excellent and the energy consumption action in brown adipocytes is higher. In order to enhance the energy-consuming action in brown adipocytes, the content ratio of tectorigenin and pinitol, in terms of mass ratio, of tectorigenin:pinitol is preferably 1:0.01 or more and 50 or less, and 1:0.05 or more and 30 or less. The following is more preferable, and 1:0.1 or more and 26 or less are especially preferable. Further, for the same reason, when tectorigenin is contained as tectorigenin, the content ratio of tectorigenin and pinitol in mass ratio, tectorigenin:pinitol, is preferably 1:0.01 or more and 50 or less, particularly Since the energy consumption action in brown adipocytes by promoting UCP1 gene expression is excellent, a ratio of 1:0.5 to 30 is particularly preferred, a ratio of 1:0.7 to 30 is more preferred, and a ratio of 1:1 to 26 is most preferred. desirable.

The amount of tectorigenins in the composition of the present invention can be measured by a high-performance liquid chromatography method (HPLC method).

For example, using YMC-Pack ODS AM12S05-2546WT (φ 4.6 × 250 mm) manufactured by YMC Co., Ltd., as a liquid medium of the mobile phase, a mixture of acetonitrile / water / acetic acid (mobile phase A volume ratio = 15: 85: 0.1 , mobile phase B volume ratio = 35: 65: 0.1), the column temperature can be 35 ° C., and the flow rate can be 1.0 ml / min.

The gradient condition can be as shown in Table A below.

[Table A]

The amount of pinitol in the composition of the present invention can be measured by HPLC method.

For example, using InertSustain NH2 (3 μm, φ3 × 250 mm) manufactured by GL Sciences Co., Ltd. as a column, and using 1 mM hydrochloric acid / acetonitrile for chromatography (volume ratio = 30/70) as a liquid medium of the mobile phase, , the column temperature can be 40 ° C., and the flow rate can be 0.5 ml / min.

In addition to tectorgenins and pinitol, the composition of the present invention may contain other commonly used components within a range that does not impair the effects of the present invention. Examples of such components include various excipients, binders, brighteners, lubricants, stabilizers, diluents, extenders, thickeners, emulsifiers, antioxidants, pH adjusters, coloring agents, flavoring agents, and additives. The content of other components can be appropriately selected according to the form of the composition of the present invention.

The composition of the present invention can be used for both oral and parenteral purposes. Examples of parenteral agents include agents administered by a method of direct administration with a catheter or the like to the stomach, and the like. However, the composition of the present invention is preferably used for oral use in that the action of the present invention related to promotion of energy consumption can be easily obtained.

When used as an oral preparation, the form includes, for example, tablets, capsules, powders, granules, liquids, granules, sticks, plates, blocks, Solid preparations, pill-like preparations, paste-like preparations, cream-like preparations, couplet-like preparations, gel-like preparations, chewable preparations, stick-type preparations, etc. are mentioned. Among these, the forms of tablets, capsules, powders, granules, and liquids are particularly preferred. Examples of oral compositions used as tablets, capsules, powders, granules, and liquids include supplements; Food additives: Containers filled in PET bottles, cans, bottles, etc. Beverages: Powdered beverages for drinking by dissolving in water (warm water), milk, fruit juice, etc. can be exemplified. These are preferable in that they are easy to eat and drink at meals or the like and can enhance palatability.

Moreover, as a specific example of the composition for oral use of this invention, food can be included as a composition for food. Examples of the food include various foods such as tea bags, bread/confectionery, and noodles, and cooked products. Breads and sweets include breads such as white bread, sweets bread, French bread, British bread, muffins, steamed buns, donuts, and waffles, cakes such as butter cakes, sponge cakes, chiffon cakes, hot cakes, chocolates, sherbet, Frozen confectionery such as ice, jelly, cookies, and the like are exemplified. As noodles, udon, somen, etc. are mentioned. Examples of the cooked food include soups such as curry, stew, miso soup and vegetable soup, their ingredients, seasonings, and the like.

In the composition of the present invention, containing 0.001% by mass or more and 40% by mass or less of pinitol and tectorigenins in the solid content in total is effective in accelerating energy consumption in brown adipocytes and in daily life. It is preferable from the viewpoint of continuous oral intake, more preferably 0.005 mass% or more and 35 mass% or less, and particularly preferably 0.01 mass% or more and 30 mass% or less. In addition, solid content is taken as the quantity remove|excluding water from a composition.

When orally ingesting the composition of the present invention, from the point of view of promoting energy consumption in brown adipocytes and easy oral intake in daily life, the oral dosage is It is preferably about 0.1 mg or more and 500 mg or less, and more preferably 0.5 mg or more and 300 mg or less per adult per day in total. In addition, the amount of intake of the composition of the present invention per serving is preferably 1 mg or more and 300 mg or less per adult per day, in terms of the total amount of pinitol and tectorigenins.

Specifically, the use form of the composition of the present invention includes so-called medicines (including quasi-drugs), general foods, nutritionally functional foods, foods for specific health use whose efficacy has been confirmed by a prescribed institution, and foods with functional claims. health food. Foods whose efficacy is indicated are sometimes collectively referred to as “functional foods”.

As shown in Examples to be described later, the composition of the present invention promotes the expression of a plurality of protein genes related to energy consumption in brown adipocytes, thereby reducing energy consumption in brown adipocytes and brown adipose tissue including the same. it is possible to promote Examples of such genes include PGC1α gene and UCP1 gene.

PGC1α (PPARγ coactivator 1α), a protein encoded by the PGC1α gene, is a protein identified as a transcriptional conjugation factor that activates transcription by the nuclear receptor PPARγ. PGC1α activates the transcription factor NRF (nuclear respiratory factor) 1/NRF2, and NRF promotes transcription of TFAM (mitochondria transcription factor), thereby activating mitochondrial biosynthesis. It is known that mitochondria increase by promoting the gene expression of PGC1?. In addition, PGC1α is a factor that binds to the receptor in the nucleus of brown adipocytes and is involved in the promotion of UCP1 gene expression. Therefore, by stimulating the gene expression of PGC1α, an action to promote energy consumption and the like can be expected through an action to increase mitochondria in brown adipocytes and an action to promote UCP1 gene expression. The PGC1α gene is sometimes described as Pgc1α.

In addition, the UCP1 gene is a gene encoding molecular uncoupling protein 1 (UCP1), and is sometimes described as Ucp1. In brown adipocytes, the UCP1 gene is expressed specifically in the mitochondria of the cells. The UCP1 gene has an activity that deconjugates oxidative phosphorylation in mitochondria, and when this is activated, energy generated from oxidative decomposition of fatty acids or glucose is directly converted into heat and consumed daily instead of going to ATP synthesis. By promoting the expression of the UCP1 gene, consumption of fatty acids in brown adipocytes is promoted, and obesity can be suppressed or eliminated.

The effect of the present invention may be to promote the expression of either the PGC1α gene or the UCP1 gene, or to promote the expression of both the PGC1α gene and the UCP1 gene. The composition of the present invention can be used for various purposes, such as promoting fat burning, promoting heat production, promoting fat metabolism, reducing body fat, and promoting energy consumption, in addition to promoting the expression of the PGC1α gene and the UCP1 gene. The use for promoting fat burning refers to the promotion of the action of converting fatty acids into heat by brown adipocytes. The promotion of heat production means, for example, promotion of heat production from neutral fat by brown adipocytes. The fat metabolism accelerating action refers to, for example, an action of qualitatively converting fat cells or adipose tissues that form an obese state into small normal adipocytes, or an action of metabolizing fatty acids by brown adipocytes. The body fat reducing action refers to an action of reducing body fat by converting fatty acids into heat, for example. Further, anti-obesity use refers to an action of reducing body fat or suppressing an increase in body fat by, for example, promoting fatty acid metabolism in brown adipocytes or brown adipose tissue. The term for promoting energy consumption refers to, for example, promotion of an action of consuming chemical energy such as fatty acids by brown adipocytes. These actions are performed through activation of PGC1α and UCP1 in brown adipocytes.

In addition, in the present invention, brown adipocytes may be located in the liver and muscles, as well as around the clavicle, chest (around the chest), shoulder (scapula and its surroundings), and the like.

In addition, the composition of the present invention may be used as a product in terms of promoting lipolysis, anti-obesity, and dieting, as long as it can be distinguished from other products, for example, to the effect of promoting lipolysis. For those who are concerned about obesity, those who are concerned about belly circumference, those who are concerned about weight, those who are concerned about belly fat (visceral fat and subcutaneous fat, etc.) Displays that appeal to those concerned, helping to lose weight, helping to reduce belly fat (visceral fat and subcutaneous fat, etc.), helping to reduce waist circumference, supporting obesity relief, supporting diet, Makes it easier to consume fat, makes it easier to burn fat, helps consume fat, helps burn fat, promotes decomposition of fat, makes it easier to break down fat, helps break down fat, etc. It means to indicate that it helps to reduce fat.

Example

Hereinafter, the present invention will be described in more detail by way of examples. However, the scope of the present invention is not limited to these examples. Hereinafter, unless otherwise specified, "%" indicates mass % and "part" indicates mass parts.

Measurement of PGC1α gene expression level

[Example 1 and Comparative Examples 1 and 2]

(1) As the test substance, tectorigenin (manufactured by Tokyo Chemical Industry Co., Ltd.) was used as tectorigenins. Moreover, as pinitol, D-pinitol (manufactured by Tokyo Chemical Industry) was used.

(2) A proliferation medium, a differentiation induction medium as a differentiation induction medium, and an adipocyte maintenance medium were used as a differentiation maintenance medium. Brown adipocyte culture kit F-8 (rat) (manufactured by Cosmo Bio, derived from interscapular brown adipose tissue) was used for the above three types of media. In addition, brown adipocytes derived from interscapular brown adipose tissue are often used when examining the function of brown adipocytes related to fat burning.

(3) A differentiation induction medium containing a test substance was prepared as follows. That is, after dissolving each test substance in DMSO, it was diluted with a differentiation induction medium, prepared so that the final concentration of DMSO was 0.5 vol%, and filter sterilization was performed. After sterilization, tectorigenin and pinitol were diluted to the concentrations shown in Table 1 using a differentiation induction medium containing 0.5 vol% DMSO.

(4) A differentiation maintenance medium containing a test substance was prepared as follows. That is, each test substance was dissolved in DMSO, diluted with a differentiation maintenance medium, prepared so that the final concentration of DMSO was 0.5 vol%, and filter sterilized. After sterilization, tectorigenin and pinitol were diluted to the concentrations shown in Table 1 using a differentiation maintenance medium containing 0.5 vol% DMSO.

(5) Rat brown adipocytes (manufactured by Cosmo Bio) were seeded in a collagen-coated 24-well plate using a growth medium at 500 µL/well so as to become 3.0 × 10 ⁴ cells/well, and incubated at 37°C for 5 ( vol/vol) % CO ₂ In an incubator, the cells were cultured until the cell density reached about 90%.

(6) After removing the medium, 500 μL/well of a differentiation induction medium containing the test substance was added, and cultured in a 37°C, 5 (vol/vol)% CO ₂ incubator for 48 hours to induce differentiation into brown adipocytes. induced.

(7) After removing the medium, 500 µL/well of a differentiation maintenance medium containing the test substance was added, and cultured in a 37°C, 5 (vol/vol) % CO ₂ incubator for 72 hours.

(8) After removing the medium, 500 µL/well of a differentiation maintenance medium containing the test substance was added, and cultured in a 37°C, 5 (vol/vol) % CO ₂ incubator for an additional 72 hours.

(9) After removing the medium, it was washed twice with PBS, RNA was recovered using RNeasy Mini Kit (manufactured by QIAGEN), and cDNA was synthesized using ReverT raAce (R) qPCR RT Master Mix (manufactured by TOYOBO) .

(10) Using the obtained cDNA as a template, quantitative real-time PCR was performed using the PGC1α gene primer (manufactured by QIAGEN) using the QuantiNova SYBR Green PCR Kit (manufactured by QIAGEN), and the amount of mRNA gene expression of PGC1α was measured. . Fig. 1 shows relative values when the value of Comparative Example 1 is set to 1 with respect to the mRNA gene expression level of PGC1α related to Example 1 and Comparative Examples 1 and 2.

[Table 1]

Measurement of UCP1 gene expression level

[Examples 2 to 4 and Comparative Examples 3 and 4]

UCP1 gene primers (manufactured by QIAGEN) were used instead of Pgc1α. In addition, as a test substance, a test substance having the composition shown in Table 2 below was used. The concentration of the test substance in the differentiation induction medium and the differentiation maintenance medium was 50 µM. Except for that point, the mRNA gene expression level of UCP1 was measured in the same manner as [Example 1 and Comparative Examples 1 and 2]. Fig. 2 shows relative values when the value of Comparative Example 3 was set to 1 with respect to the expression level of the mRNA gene of UCP1 related to Examples 2 to 4 and Comparative Examples 3 and 4.

[Table 2]

As shown in Figs. 1 and 2, when brown adipocytes were induced and differentiated in the presence of the composition of the present invention in which tectorigenins and pinitol were combined, the expression levels of PGC1α gene and UCP1 gene, tectory It greatly exceeded all cases where genin and pinitol were used alone. In particular, for the UCP1 gene, which plays an important role in energy consumption, a synergistic expression promoting effect was shown by using tectorgenins and pinitol in combination.

Therefore, it is clear that the composition of the present invention exhibits an excellent effect of promoting energy consumption in brown adipocytes and is excellent as an anti-obesity agent.

Granules (3000 mg per packet) composed of the following components were prepared. An excellent anti-obesity effect is obtained by suspending and ingesting the obtained granules in water twice a day, one packet per time.

[Table 3]

Granules (2000 mg per packet) consisting of the following ingredients were prepared. An excellent anti-obesity effect is obtained by suspending and ingesting the obtained granules three times a day, one packet per time in warm water.

[Table 4]

A tablet (200 mg per tablet) consisting of the following ingredients was prepared. An excellent anti-obesity effect is obtained by ingesting the obtained tablet twice a day, 4 tablets per time.

[Table 5]

A tablet (300 mg per tablet) consisting of the following ingredients was prepared. An excellent anti-obesity effect is obtained by ingesting the obtained tablet once a day, 5 tablets per time.

[Table 6]

A capsule (300 mg per tablet) consisting of the following ingredients was prepared. An excellent anti-obesity effect is obtained by ingesting the obtained capsule twice a day, 2 tablets per time.

[Table 7]

Since the composition of the present invention can be expected to have a high degree of anti-obesity effect, its industrial usefulness is high.

Claims (10)

An anti-obesity composition containing tectorigenin and pinitol. According to claim 1,
An anti-obesity composition wherein the content ratio of tectorigenin and pinitol is tectorigenin:pinitol = 1:0.1 or more and 26 or less in terms of mass ratio. According to claim 1 or 2,
An anti-obesity composition wherein the tectorigenin is tectorigenin. A composition for reducing body fat or promoting fat metabolism, comprising tectorigenin and pinitol. According to claim 4,
A composition for reducing body fat or promoting fat metabolism by promoting consumption of fatty acids in brown adipocytes. A composition for promoting fat burning, promoting heat production, or promoting energy consumption, containing tectorigenin and pinitol. According to claim 6,
A composition for promoting fat burning, heat production, or energy consumption by promoting fatty acid consumption in brown adipocytes. An oral composition containing tectorigenins and pinitol. Use of tectorgenins and pinitol for the production of functional foods for obesity improvement. A method for reducing body fat, promoting fat metabolism or promoting fat burning, using a composition comprising tectorgenins and pinitol.

Images